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Abstract 23 
This study investigated the capacity of an anthocyanin-rich fraction (ACN-RF) from blueberry, single 24 
anthocyanins (cyanidin, delphinidin and malvidin-3-glucoside; Cy, Dp and Mv-3-glc) and related 25 
metabolites (protocatechuic, gallic and syringic acid; PrA, GA and SA) to resolve an inflammation-26 
driven adhesion of monocytes (THP-1) on endothelial cell (HUVECs) and secretion of cell adhesion 27 
molecules E-selectin and vascular cell adhesion molecule 1 (VCAM-1). 28 
The adhesion of THP-1 to HUVECs was induced by tumour necrosis factor α (TNF-α, 100 ng mL-1). 29 
Subsequently, ACN-RF, single ACNs and metabolites (from 0.01 to 10 μg mL-1) were incubated for 30 
24 h. The adhesion was measured in a fluorescence spectrophotometer. E-selectin and VCAM-1 were 31 
quantified by ELISA. No toxicological effects were observed for the compounds and the doses tested. 32 
ACN-RF and Mv-3-glc reducedTHP-1 adhesion at all the concentrations with the maximum effect at 33 
10 μg/ml (-60.2% for ACNs and-33.9% for Mv-3-glc). Cy-3-glc decreased the adhesion by about 34 
41.8% at 10 μg mL-1, while PrA and GA reduced the adhesion of THP-1 to HUVECs both at 1 and 35 
at 10 μg mL-1 (-29.5% and -44.3% for PrA, respectively, and -18.0%and -59.3% for GA, 36 
respectively). At the same concentrations a significant reduction of E-selectin, but notVCAM-1 37 
levels, was documented. No effect was observed following Dp-3-glc and SA supplementation. 38 
Overall, ACNs and metabolites seem to resolve, in a dose-dependent manner, the inflammation-39 
driven adhesion of THP-1 to HUVECs by decreasing E-selectin concentrations. Interestingly, Mv-3-40 
glc was active at physiologically relevant concentrations.  41 
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1. INTRODUCTION 42 
Anthocyanins (ACNs) are a group of abundant and widely consumed flavonoids providing the red, 43 
blue, and violet colours in fruit- and vegetable-based food products. The dietary intake of ACNs is 44 
up to 9-fold higher than that of other dietary flavonoids. Epidemiological studies have found an 45 
inverse association between the consumption of ACNs and risk of cardiovascular diseases [1-6]. Their 46 
role in prevention of cardiovascular disease is strongly linked to the protection against oxidative stress 47 
and inflammation [7-10]. Atherosclerosis is the main underlying cause of cardiovascular disease in 48 
humans. The early stage, i.e. atherogenesis, is characterized by activation of endothelial cells to 49 
express cell adhesion molecules and recruit monocytes. This process is identical to the vascular 50 
responses to tissue inflammation, which resolves when the underlying cause of inflammation (e.g. an 51 
invading infectious agent) has been removed. However, the prolonged inflammatory milieu in early 52 
atherosclerotic foci stimulates the transformation of monocytes foam cell [11]. 53 
It has been shown that ACNs prevent endothelial cell dysfunction by modulating the expression and 54 
activity of several enzymes involved in nitric oxide production [12-13]. Furthermore, recent evidence 55 
suggests that ACNs can down-regulate the expression of adhesion molecules and prevent the adhesion 56 
of monocytes to endothelial cells challenged by pro-inflammatory cytokines [12;14]. The absorption 57 
of ACNs is low (<1%), but most of them are rapidly transformed by human gut to metabolic products, 58 
reaching a plasmatic concentration much higher than that of parental ACNs, indicating their 59 
contribution in the biological activity observed should be considered [15]. We have reported that 60 
ACNs and phenolic acid-rich fractions from a wild blueberry powder counteracted the adhesion of 61 
monocyte to endothelial cells in a pro-inflammatory milieu [16]. In the same study, single ACNs and 62 
certain gut metabolites (delphinidin-3-glc and gallic acid) prevented the attachment of monocytes to 63 
endothelial cells, while malvidin-3-glc and syringic acid exacerbated the adhesion process [16]. 64 
In the present study, we investigated the capacity of the same ACNs to resolve an inflammatory 65 
process by reducing the adhesion of monocytes to activated endothelial cells and the production of 66 
vascular adhesion molecules as potential mechanisms in the atherogenesis. To this end, monocytic 67 
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(THP-1) cells were cultured with human umbilical endothelial cells (HUVECs) in the presence of the 68 
pro-inflammatory cytokine tumour necrosis factor-alpha (TNF-α) to promote the expression of cell 69 
adhesion molecules and interaction between the cells. TNF-α is produced by immune cells and it 70 
stimulates endothelial cells to express adhesion molecules, including E-selectin, vascular cell 71 
adhesion molecule-1 (VCAM-1) as well as chemokines (i.e. interleukin-8 and monocyte 72 
chemoattractant protein-1) that promote the recruitment of monocytes to inflamed luminal 73 
endothelium and induce their adhesion to endothelial cells at the site of activation [17]. The 74 
expression of E-selectin occurs early following stimulation of pro-inflammatory cytokines such as 75 
TNF- in endothelial cells (4 and 6 h after stimulation and remains elevated up to 24 h) [18]. E-76 
selectin mediates the initial attachment of free-flowing leukocytes to the arterial wall, while the 77 
expression of VCAM-1 provides a stronger interaction between leukocytes and endothelial cells and 78 
mediates the transmigration of the cells into the tissue [18-19].Cytokine-induced expression, and 79 
subsequent down-regulation after cessation of exposure, in endothelial cells occurs later for VCAM-80 
1 than E-selectin [20]. We assessed the production of E-selectin and VCAM-1 to cover this “early” 81 
and “late” phase of the endothelial production of cell adhesion proteins. 82 
2. MATERIALS AND METHODS 83 
2.1 Reagents 84 
Standard of cyanidin, delphinidin and malvidin-3-glucoside (Cy, Dp and Mv-3-O-glc) were obtained 85 
from Polyphenols Laboratory (Sandes, Norway), while those of gallic, protocatechuic, and syringic 86 
acid (GA, PrA and SA) from Sigma-Aldrich (St. Louis, MO, USA). Human Endothelial Cells Basal 87 
Medium and Human Endothelial Cells Growth Supplement were purchased from Tebu-Bio 88 
(Magenta, MI, Italy). Hanks balanced salt solution, foetal bovine serum (FBS), TNF-α were from 89 
Sigma-Aldrich (St. Louis, MO, USA). Gentamin, RPMI-1640, HEPES, Sodium Pyruvate, trypsin-90 
EDTA were from Life Technologies (Monza Brianza, MB, Italy)while the 5-91 
Chloromethylfluorescein Diacetate (CellTrackerTM Green CMFDA) from Invitrogen (Carlsbad, CA, 92 
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USA).Hydrochloric acid and methanol were purchased from Merck (Darmstadt, Germany), while 93 
water was obtained from a Milli-Q apparatus (Millipore, Milford, MA).  94 
2.2 Preparation and characterization of the ACN-rich fraction, single anthocyanins and 95 
metabolites 96 
The extraction of the ACN-rich fraction from a wild blueberry powder (Future Ceuticals, Momence, 97 
IL, USA)was performed as reported by Del Bo’ et al. [16]. The fraction was characterized for the 98 
content of ACNs, phenolic acids as well as other bioactives as previously published [16]. The total 99 
ACN content was  45.11 ± 0.35 mg mL-1 and constituted predominantly of Mv-3-glc (about 26%), 100 
Mv-3-gal (15%) followed by Dp-3-glc (9%) and Petunidin-3-glc (8%). No phenolic acids or other 101 
bioactives were detectable. 102 
Lyophilized standards of Mv, Cy, Dp-3-O-glc (native compounds) and SA, PrA and GA 103 
(corresponding metabolites) are shown in Figure 1. The standards were prepared as previously 104 
reported [16]. These single compounds were tested since found in the blood stream of volunteers after 105 
consumption of a blueberry portion [21]. 106 
2.3 Cell culture and viability 107 
Human umbilical vein endothelial cells (HUVECs; Tebu-Bio SrL, Magenta, MI, Italy) were cultured 108 
in endothelial cell growth medium kit containing 2% serum at 37°C and 5% CO2 until reaching 109 
confluence (generally after 1 week). THP-1 cells were grown in a complete RPMI cell media (RPMI-110 
1640 medium supplemented with 1% HEPES, 1% sodium pyruvate, 0.1% gentamicin, and 10% FBS 111 
at 37 °C and 5% CO2 and maintained in culture for up to 3 months.  112 
Cell viability was performed for each compound and concentration by Trypan blue and (3-(4,5-113 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, showing cells viability above 114 
90% as previously published [16]. 115 
2.4 THP-1 adhesion to HUVECs 116 
An aliquot of 2x104 HUVECs was seeded on 0.1% gelatine pre-coated 96-well black plate and 117 
maintained at 37°C and 5% CO2 for 24h.Subsequently, monocytic (2x10
6) THP-1 cells (American 118 
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Type Culture Collection, Manassas, VA, USA) were re-suspended in 1 mL serum free RPMI cell 119 
medium (containing 1% HEPES, 1% sodium pyruvate, 0.1% gentamicin) and labelled with 120 
CellTrackerTM Green CMFDA (1 µM, 30 min at 37°C and 5% CO2). THP-1 were washed twice, re-121 
suspended in HUVEC medium (2x105 cells mL-1density) and added to HUVECs with TNF-α (100 122 
ng mL-1). After 24 h incubation (37°C, 5% CO2) medium was removed and 200 μL of new medium, 123 
containing the single ACNs (Mv, Cy and Dp-3-glucoside) and their corresponding metabolites (SA, 124 
PrA and GA, respectively) was added at the concentrations of 0.01, 0.1, 1 and 10µg mL-1 for 24 h at 125 
37°C and 5% CO2. Then, media was collected and stored at -80°C until analysis. Cells were rinsed 126 
twice before the measure of the fluorescence (excitation: 485 nm, emission: 538 nm; mod. F200 127 
Infinite, TECAN Milan, Italy). The level of fluorescence is associated with the number of labeled-128 
THP-1 cells attached to the HUVECs. The results derive from three independent experiments in 129 
which each concentration was tested in quintuplicate. Data are reported as fold increase compared to 130 
the control cells without stimulation with TNF-α or bioactive compounds.  131 
2.5 Visualization at the microscope 132 
 133 
The adhesion of THP-1 to HUVECs was visualized at the microscope. HUVEC (4x104/well) were 134 
seeded onto 0.1 % gelatin pre-coated 12-well plate for 24 h. THP-1 (8x104/well) were stained with 135 
CellTrackerTM Green CMFDA and added with TNF-α to HUVECs as previously reported. After 136 
treatment, cells were rinsed with Hank solution in order to remove the non adherent cells and 137 
inspected with an inverted wide-field microscope with 10 × magnifications. 138 
 139 
2.6 Determination of soluble VCAM-1 and E-selectin concentration in cell supernatant 140 
The concentrations of soluble VCAM-1 and E-selectin, in recovered cell culture supernatants, were 141 
quantified by ELISA kits according to the manufacture’s instruction. The analyses were conducted 142 
in quadruplicate and the results derived from three independent experiments. 143 
2.7 Statistical analysis 144 
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One-way ANOVA was applied to verify the effect of the different concentrations of ACNs and 145 
metabolites on fold increase THP-1 adhesion to HUVECs and on percentage changes in soluble 146 
VCAM-1 and E-selectin concentration. Differences between treatments was assessed by the Least 147 
Significant Difference (LSD) test with p<0.05 as level of statistical significance. Results are reported 148 
as mean ± standard error of mean. The statistical analysis was performed by means of STATISTICA 149 
software (Statsoft Inc., Tulsa, OK, USA). 150 
 151 
3. RESULTS 152 
3.1 Effect of ACN-rich fraction on monocytes adhesion process 153 
In Figure 2 are reported the effects of ACN-RF on THP-1 adhesion to HUVECs. There was a 154 
significant increase in THP-1 cell adhesion to HUVECs following stimulation with TNF-α 155 
(p<0.0001), while the incubation with ACN-RF significant reduced the process (p<0.0001) at all the 156 
concentrations tested (from 0.01 to 10 μg mL-1).The maximum effect of reduction was observed at 157 
10 µg mL-1 (-60.2%) with respect to the control with TNF-α.  158 
 159 
3.2Effect of anthocyanins and metabolic products on monocytes adhesion process 160 
Figure 3 (A-C) shows the results on THP-1 adhesion to HUVECs after incubation with the single 161 
ACNs. The incubation with Mv-3-glc significantly decreased (p<0.0001) the adhesion of monocytes 162 
to HUVECs at all the concentrations tested (from 0.01 to 10 μg mL-1) compared to TNF- (Fig. 3A). 163 
The maximum reduction was observed for the concentration at 10 µg mL-1 (-33.9%; p<0.0001) as 164 
also reported in Figure 4 that shows the adhesion of labelled THP-1 to endothelial cells following 24 165 
h stimulation with TNF-α (A), TNF-α + 10 µg/mL Mv-3-glc (B) and control (C).  Regarding Cy-3-166 
glc, a significant reduction in the adhesion of THP-1 to HUVEC was observed only at 10 μg mL-1 (-167 
41.8%; p<0.01) (Fig. 3B), while no significant effect was found for Dp-3-glc (Fig. 3C).  168 
Figure 5 (A-C) reports the results on THP-1 adhesion to HUVECs after incubation with SA, PrA and 169 
GA (metabolites of Mv-3-glc, Cy-3-glc, and Dp-3-glc, respectively). No significant effect was 170 
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observed following SA supplementation (Fig. 5A) in line with the results reported in Fig. 4 that shows 171 
the adhesion of labelled THP-1 to endothelial cells following stimulation with TNF-α + 10 µg/mL 172 
SA (D). The supplementation with PrA (Fig. 5B) and GA (Fig. 5C) significantly decreased the 173 
adhesion of monocytes to endothelial cellsat 1 µg mL-1 (-18.0%; p<0.05 for GA, -29.5%; p<0.05 for 174 
PrA) and 10 µg mL-1 (-59.3%; p<0.001 for GA, -44.3%; p<0.01 for PrA) compared to TNF-.  175 
3.3 Effect of anthocyanins and metabolic products on soluble E-selectin and VCAM-1 levels in 176 
cell supernatant 177 
Table 1 shows the levels of E-selectin quantified in the cell supernatant following incubation with 178 
ACNs and metabolites. There was a significant increase in E-selectin following stimulation with 179 
TNF- compared to negative control (without TNF-). The incubation of cells with Mv-3-glc 180 
significantly reduced (p<0.001) the levels of E-selectin at all concentrations tested. This reduction 181 
was not concentration dependent and the maximum effect was observed at 0.01 and 0.1 μg mL-1 (-182 
66% and -67%, respectively). Cy-3-glc reduced the E-selectin concentration at 10μg mL-1 (-72%; 183 
p<0.01), PrA at 1 and 10 μg mL-1 (-74 and -76%; p<0.001, respectively), and GA at 1μg mL-1 (-34%; 184 
p<0.01) and 10 µg mL-1 (-40%; p<0.01). No effect was found after Dp-3-glc and SA incubation in 185 
line with the lack of the positive effect on the adhesion of THP-1 to HUVECs. 186 
The levels of VCAM-1 quantified in the cell supernatant following incubation with ACNs and 187 
metabolites are reported in Table 2. There was a significant increase (p<0.05) following stimulation 188 
with TNF- compared to negative control (without TNF-). However, no significant effect was 189 
observed following incubation with ACNs and gut metabolites. 190 
 191 
4. DISCUSSION 192 
Chronic inflammation is a common factor in endothelial dysfunction and atherosclerosis 193 
[11;22]. Different cell models have been used to assess the interaction between endothelial cells and 194 
monocytic cell lines (e.g. THP-1, U937, MonoMAC) or freshly isolated leukocytes as early event in 195 
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atherosclerosis. We obtained a two-fold increase in attachment of THP-1 cells to HUVECs which is 196 
in line with earlier observations with the same co-culture [23-24]). The TNF-induced attachment of 197 
monocytic U937 cells to endothelial cells seems to be in the range of a 2-3-fold increase [25-26], 198 
whereas MonoMAC cells may have higher sensitivity and response to TNF-mediated adhesion to 199 
HUVECs (i.e. 6-fold increase at 10 µg/mL TNF-) [27] Poussin 2014).  200 
In the last years, several studies have focused on the mechanisms through which polyphenols 201 
modulate the adhesion process and the vascular inflammation [28-29]. Here we evaluated the capacity 202 
of Mv, Cy, and Dp-3-glc, and corresponding metabolites, to resolve an inflammation-driven adhesion 203 
of THP-1 to HUVECs and the production of vascular adhesion molecules. The results obtained 204 
documented that ACN-RF and Mv-3-glc had an effect at all the concentrations tested, while Cy-3-205 
glc, GA and PrA resolved the adhesion process only at the high concentrations (1 and 10 µg mL-206 
1).These findings are in contrast with those documented in a previous experiment, in which Mv-3-glc 207 
led to an exacerbation of the adhesion process, while Cy and PrA failed to affect the interaction 208 
between monocytes and endothelial cells [16]. In light of our results, we hypothesize that these 209 
compounds are more active in resolving than preventing the adhesion process. In vitro studies 210 
reported a beneficial effect on the prevention of atherogenesis only at supra-physiological 211 
concentrations in according with our findings [25-33]. However, recent in vitro studies showed a 212 
positive effect of ACNs, phenolic acids and gut metabolites also at physiological relevant 213 
concentrations [34-35]. For example, Kraga et al., [35] reported that Cy-3-glucoside, galattoside and 214 
arabinoside, as well as Dp and Peondin-3-glucoside and phenolic acids/gut metabolites (vanillic acid, 215 
ferulic acid, hippuric acid, 4-hydroxybenzaldehyde and PrA) decreased the adhesion of monocytes to 216 
HUVECs from 0.1 to 2 µM. The effect was also confirmed when ACNs and phenolic acids were used 217 
as a mix, suggesting an additive effect of the compounds.  218 
In our experimental conditions, the reduction of adhesion of THP-1 to TNF-α-activated 219 
HUVECs after supplementation with ACNs and metabolites can be attributed to different non-220 
specific and/or specific complex mechanisms of action. Further insight into the mechanisms can be 221 
10 
 
gained by high content screening and transcriptomics of inflammatory and oxidative stress pathways 222 
as used in co-culture studies of monocytes and HUVECs [36]. Inhibition of NF-κB activity could 223 
have reduced the synthesis of numerous cytokines by decreasing the levels of inflammation at 224 
endothelial level. In this regard, the inhibition of pro-inflammatory cytokines such as TNF- and the 225 
reduction of leukocyte adhesion to endothelial cells are key mechanisms in the control of 226 
atherogenesis and atherosclerosis. Moreover, ACNs have a pivotal role in the modulation of mitogen-227 
activated protein kinase pathways implicated in several cellular processes including proliferation, 228 
differentiation, apoptosis, cell survival, cell motility, metabolism, stress response and inflammation 229 
[8]. Alternatively, the use of ACNs and phenolic acids may repress the secretion of chemokine (C-C 230 
motif) ligand 2 (MCP-1), which pilots the migration of monocytes toward the intracellular cleft 231 
between adjacent endothelial cells, or reduce the production of adhesion molecules such as VCAM-232 
1, ICAM-1 and E-selectin that regulate the recruitment of monocytes into atherosclerosis-prone area. 233 
In our experimental conditions, we found that the alleviating effects on cell adhesion, induced by the 234 
single compounds, were associated with changes in the levels of E-selectin, but not VCAM-1 levels. 235 
We found that Mv-3-glc was more effective in reducing the production of E-selectin compared to the 236 
other compounds tested. In fact, the decrease was observed both at low and high concentrations, while 237 
for Cy-3-glc, PrA and GA the effects were detected only at the high doses. The increased E-selectin 238 
production at high concentration may be due to a stimulation of the cells as also shown in a previous 239 
study where Mv-glc led to an exacerbation of the adhesion process [16]. Dp-3-glc and SA 240 
supplementation did not show any reduction in line with the lack of an effect on THP-1 adhesion to 241 
HUVECs. Conversely, different studies report changes in the expression/levels of VCAM-1, ICAM-242 
1, other than E-selectin, following ACNs and metabolites supplementation; most of them showed a 243 
beneficial effect only at supra-physiological concentrations. For example, Ferrari et al., [38] 244 
demonstrated that Cy-3-glc (20 μM) counteracted the acute pro-inflammatory effects of TNF-α in 245 
HUVECs, reduced leukocyte recruitment from microcirculation, and decreased the gene expression 246 
levels of E-selectin and VCAM-1. Huang et al., [39] reported that the supplementation with different 247 
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concentrations of Mv-3-glc (1-100µM) inhibited the TNF-α-induced inflammatory response in a 248 
concentration-dependent manner and reduced the production of MCP-1, ICAM-1 and VCAM-1 in 249 
endothelial cells. Nizamutdinova and colleagues [40] found that ACNs from black soybean seed coats 250 
(rich in Cy, Dp and Petunidin-3-glucoside) reduced TNF--mediated VCAM-1 induction in a 251 
concentration-dependent manner (10, 50, and 100 μg/mL), but not ICAM-1 in HUVEC. Amin et al., 252 
[41] showed that simulated human vascular endothelial cells with oxidized-LDL and co-treated with 253 
Cy-3-glc (0.1, 1, and 10 µM concentrations) significantly reduced VCAM-1 protein production. In 254 
addition, phenolic acids affected the expression and the levels of adhesion molecules. Warner et al., 255 
[42] tested the capacity of 20 different phenolic acids to reduce the secretion of VCAM-1 in activated 256 
TNF-α endothelial cells showing a significant effect for PrA in a concentration-dependent manner (1-257 
100 μM). Similar results were also found following vanillic, isovanillic, ferulic, hyppuric acids and 258 
derivates supplementation [37;41-42]. 259 
 260 
5. CONCLUSIONS  261 
In conclusion, this study documented the capacity of Mv-3-glc, Cy-3-glc, PrA and GA to reverse an 262 
atherogenic condition. This reduction can be explained by a significant decrease in the adhesion of 263 
monocytes to endothelial cells and in the production of E-selectin, but not VCAM-1 in the present 264 
short-term incubation period. Mv-3-glc seems the most potent anti-atherogenic compound since it 265 
actives both at supraphysiological and physiological concentrations.  266 
 267 
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FIGURE CAPTION  396 
 397 
Figure 1- Chemical structure of anthocyanins and their metabolites used in this study 398 
 399 
Legend: Mv-3-glc, malvidin-3-glucoside; Cy-3-glc, cyanidin-3-glucoside; Dp-3-glc, delphinidin-3-400 
glc; SA, syringic acid; PrA, protocatechuic acid; GA, gallic acid; 401 
  402 
19 
 
Figure 2- Effect of ACN-RF (0.02 and 18.9 μM, expressed as Mv-3-glc as the main compound) on 403 
THP-1 adhesion to HUVECs. Results are expressed as mean ± standard error of mean. a,b,cBar graphs 404 
reporting different letters are significantly different (p ≤ 0.05).  405 
 406 
Legend: TNF-α tumor necrosis factor alpha, ACN-RF anthocyanin-rich fraction, NO TNF-α (control).  407 
 408 
  409 
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Figure 3- Effect of A) Mv-3-glc (0.02-18.9 μM), B) Cy-3-glc (0.03–25.9 μM) and C) Dp-3-glc (0.02–410 
19.9 μM) on THP-1 adhesion to HUVECs. Results are expressed as mean ± standard error of mean. 411 
a,b,cBar graphs reporting different letters are significantly different (p ≤ 0.05).  412 
 413 
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Legend: TNF-α, tumor necrosis factor alpha; Mv-3-glc, malvidin-3-glucoside; Cy-3-glc, cyanidin-414 
3-glucoside; Dp-3-glc, delphinidin-3-glc; NO TNF-α (control). 415 
Figure 4 Visualization of THP-1 adhesion to HUVEC following 100 ng mL−1 of TNF-α (a), TNF-α 416 
+10 μg mL−1 of Mv-3-glc (b), TNF-α + 10 μg mL−1 of SA (c), and NO TNF-α (d). 417 
Legend: TNF-α, tumor necrosis factor alpha; Mv-3-glc, malvidin-3-glucoside; SA, syringic acid; NO 418 
TNF-α (control). Round yellow cells represent THP-1 cells adhered to HUVECs. The black arrows 419 
indicate an example of adhered THP-1, while the red arrows indicate HUVECs.   420 
 421 
Figure 5- Effect of A) SA (0.05-50.5 μM), B) PrA(0.03–64.9 μM) and C) GA (0.03–58.8 μM) on 422 
THP-1 adhesion to HUVECs. Results are expressed as mean ± standard error of mean. a,b,cBar graphs 423 
reporting different letters are significantly different (p ≤ 0.05).  424 
22 
 
 425 
Legend: TNF-α, tumor necrosis factor alpha; SA, syringic acid; PrA, protocatechuic acid; GA, gallic 426 
acid; NO TNF-α (control).    427 
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Table 1: Effect of ACNs and metabolites on the levels of E-selectin 428 
 Compounds  
Concentrations Mv-3-glc Cy-3-glc Dp-3-glc SA PrA GA 
0.01 µg mL-1 107±15a 311±13a 308±11a 299±15a 290±13a 304±15a 
0.1 µg mL-1 104±16a 297±15a 299±22a 297±15a 257±12a 321±11a 
1 µg mL-1 186±12a 300±14a 295±12a 297±16a 83±15b 206±10b 
10 µg mL-1 149±24a 83±10b 315±16a 295±14a 74±18b 188±17b 
(TNF-α) 100 ng mL-1 316±16b 307±11a 318±12a 316±16a 307±11a 318±12a 
(TNF-α) 0 ng mL-1 59±9.0c 64±10c 65±4.6b 59±9.0b 64±10c 65±4.6c 
 429 
Data derived from three different experiments and each concentration tested in triplicate. Each ACN and metabolite was tested in presence of TNF-α stimulus. Results are expressed 430 
as mean ± SEM. Mv-3-glc, malvidin-3-glucoside; Cy-3-glc, cyanidin-3- glucoside,Dp-3-glc, delphinidin-3-glc;SA, syringic acid, PrA, protocatechuic acid; GA, gallic acid;TNF-α, 431 
tumor necrosis factor alpha. a,b,cData with different letters are significantly different (p <0.05). Concentration range: 0.02-18.9 µM for Mv-3-glc, 0.02–19.9 µM for Dp-3-glc, 0.02–432 
20.6 µM for Cy-3-glc, 0.25 and 50.5 μM for SA, 0.32–64.9 μM for PrA and 0.29–58.8 μM for GA.  433 
 434 
Table 2: Effect of ACNs and metabolites on the levels of VCAM-1  435 
 Compounds  
Concentrations Mv-3-glc Cy-3-glc Dp-3-glc SA PrA GA 
0.01 µg mL-1 13.16±0.78 15.10±0.35 15.98±0.76 15.43±0.41 14.38±0.17 16.98±1.76 
0.1 µg mL-1 13.64±0.04 14.56±0.23 15.80±1.10 16.59±0.28 14.83±0.53 14.99±1.90 
1 µg mL-1 14.15±0.33 14.65±0.20 16.94±0.51 18.85±0.23 15.28±0.42 16.64±0.71 
10 µg mL-1 14.38±0.11 15.10±0.24 16.30±0.40 17.45±0.29 16.19±0.37 16.26±0.80 
(TNF-α) 100 ng mL-1 15.74±1.14 15.17±1.08 16.97±1.81 15.74±1.14 15.17±1.08 16.97±1.81 
(TNF-α) 0 ng mL-1 11.04±0.37* 10.99±0.35* 11.27±0.28* 11.04±0.37* 10.99±0.35* 11.27±0.28* 
 436 
Data derived from three different experiments and each concentration tested in triplicate. Each ACN and metabolite was tested in presence of TNF-α stimulus. Results are expressed 437 
as mean ± SEM. Mv-3-glc, malvidin-3-glucoside; Cy-3-glc, cyanidin-3- glucoside, Dp-3-glc, delphinidin-3-glc; SA, syringic acid, PrA, protocatechuic acid; GA, gallic acid; TNF-438 
α, tumor necrosis factor alpha.*Significantly different (p <0.05). Concentration range: 0.02-18.9 µM for Mv-3-glc, 0.02–19.9 µM for Dp-3-glc, 0.02–20.6 µM for Cy-3-glc, 0.25 439 
and 50.5 μM for SA, 0.32–64.9 μM for PrA and 0.29–58.8 μM for GA.  440 
